临床神经外科杂志2017，Vol.14Issue(5)：374-377,4.DOI:10.3969/j.issn.1672-7770.2017.05.013
早期应用重组活化凝血因子Ⅶ对重型颅脑外伤的临床疗效
Curative effect of early administration of recombinant activated factorⅦ treating patients with severe traumatic brain injury
摘要
Abstract
Objective To investigate the curative effect of recombinant activated factor Ⅶ ( rFⅦa) on treating patients with severe traumatic brain injury (TBI).Methods 40 patients with TBI were randomly divided into the treatment group (n=20) and the control group (n=20).Patients in the control group accepted only conventional treatment , while the treatment group accepted an addition dose rFⅦa (40 mg/kg) on admission.The observation window was 168 hours for change of coagulation parameters and adverse events .And the other changes in intraoperative blood loss , reoperation rate ,mortality ,3 months Glasgow outcome scale ( GOS ) score were observed .Results Compared with the control group ,differences were significant with regard to PT ,APTT,FDP,DD ( all P<0.05).The intraoperative blood loss was (500 ±194.3) ml and (1030 ±427.0)ml,the 168 h concentrated red cell transfusion amount was (1.70 ±1.72)u and (3.61 ±1.73)u,the reoperation rate was 15%(3/20) and 45%(9/20),the mortality was 15%(3/20) and 45%(9/20),the 3 months GOS score was (3.20 ±1.28) and (2.35 ±1.31) in the treatment and control group respectively (all P<0.05).Conclusion Early application of rFⅦa for patients with TBI can improve blood coagulation function , reduce reoperation rate and mortality , which can improve the clinical efficacy and activity ability of daily living .关键词
重型颅脑外伤/重组活化凝血因子Ⅶ/凝血功能障碍Key words
severe traumatic brain injury/recombinant activated factor Ⅶ/coagulation disorders分类
医药卫生引用本文复制引用
周立田,杨平来,丁俊宏,张源源,薛元峰..早期应用重组活化凝血因子Ⅶ对重型颅脑外伤的临床疗效[J].临床神经外科杂志,2017,14(5):374-377,4.基金项目
南京市医学科学发展课题(YKK13199) （YKK13199）
